iBio Inc. [AMEX: IBIO] loss -3.42% on the last trading session, reaching $1.13 price per share at the time. The company report on December 11, 2020 that iBio Announces Closing of its Public Offering of Common Stock.
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, announced the closing of its underwritten public offering of approximately 29.7 million shares of its common stock for gross proceeds of $35.0 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by iBio. In addition, iBio has granted the underwriter a 30-day option to purchase up to approximately 4.4 million additional shares of its common stock.
Cantor Fitzgerald & Co. was the sole book-running manager for the offering. Roth Capital Partners acted as financial advisor to iBio.
iBio Inc. represents 182.11 million in outstanding shares, while the company has a total market value of $231.37 million with the latest information. IBIO stock price has been found in the range of $1.12 to $1.18.
If compared to the average trading volume of 10.72M shares, IBIO reached a trading volume of 11042680 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about iBio Inc. [IBIO]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for IBIO shares is $2.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on IBIO stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Alliance Global Partners have made an estimate for iBio Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on June 26, 2020.
The Average True Range (ATR) for iBio Inc. is set at 0.12, with the Price to Sales ratio for IBIO stock in the period of the last 12 months amounting to 121.77. The Price to Book ratio for the last quarter was 2.31, with the Price to Cash per share for the same quarter was set at 0.41.
Trading performance analysis for IBIO stock
iBio Inc. [IBIO] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -13.74. With this latest performance, IBIO shares dropped by -36.52% in over the last four-week period, additionally sinking by -27.56% over the last 6 months – not to mention a rise of 482.47% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for IBIO stock in for the last two-week period is set at 29.16, with the RSI for the last a single of trading hit 24.36, and the three-weeks RSI is set at 32.95 for iBio Inc. [IBIO]. The present Moving Average for the last 50 days of trading for this stock 1.7108, while it was recorded at 1.1820 for the last single week of trading, and 1.9434 for the last 200 days.
iBio Inc. [IBIO]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and iBio Inc. [IBIO] shares currently have an operating margin of -854.88. iBio Inc.’s Net Margin is presently recorded at -1003.60.
Return on Total Capital for IBIO is now -23.97, given the latest momentum, and Return on Invested Capital for the company is -28.32. Return on Equity for this stock declined to -55.65, with Return on Assets sitting at -26.35. When it comes to the capital structure of this company, iBio Inc. [IBIO] has a Total Debt to Total Equity ratio set at 58.12. Additionally, IBIO Total Debt to Total Capital is recorded at 36.76, with Total Debt to Total Assets ending up at 34.94. Long-Term Debt to Equity for the company is recorded at 57.13, with the Long-Term Debt to Total Capital now at 36.13.
Reflecting on the efficiency of the workforce at the company, iBio Inc. [IBIO] managed to generate an average of -$4,109,750 per employee. Receivables Turnover for the company is 0.57 with a Total Asset Turnover recorded at a value of 0.03.iBio Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 16.70 and a Current Ratio set at 16.80.
An analysis of insider ownership at iBio Inc. [IBIO]
There are presently around $19 million, or 8.70% of IBIO stock, in the hands of institutional investors. The top three institutional holders of IBIO stocks are: BLACKROCK INC. with ownership of 5,448,105, which is approximately 25.874% of the company’s market cap and around 0.20% of the total institutional ownership; VANGUARD GROUP INC, holding 2,675,662 shares of the stock with an approximate value of $3.02 million in IBIO stocks shares; and GEODE CAPITAL MANAGEMENT, LLC, currently with $1.69 million in IBIO stock with ownership of nearly 113.212% of the company’s market capitalization.
Positions in iBio Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 62 institutional holders increased their position in iBio Inc. [AMEX:IBIO] by around 6,405,158 shares. Additionally, 23 investors decreased positions by around 622,890 shares, while 9 investors held positions by with 8,957,581 shares. The mentioned changes placed institutional holdings at 15,985,629 shares, according to the latest SEC report filing. IBIO stock had 33 new institutional investments in for a total of 1,607,397 shares, while 14 institutional investors sold positions of 493,508 shares during the same period.